Multiple Myeloma: Educating Patients on Oral Toxicity Management

EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

EP: 2.Overview of Relapsed/Refractory Multiple Myeloma

EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM

EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma

EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities

Now Viewing

EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management

EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma

EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma

This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.

Catamero observes taste changes with talquetamab during step-up dosing, underscoring the need to set expectations about oral toxicities up front through detailed patient counseling. Good oral hygiene is stressed along with prophylactic interventions like saliva substitutes, dexamethasone rinses (used properly), nutritional consultations if there is a weight loss risk, and prompt treatment of suspected infections. Experimental icing and other anecdotal measures also continue to be tried. Rodriguez recommends combining any dexamethasone rinse with nystatin to prevent thrush. Repeated patient education with take-home references is vital. Overall, multifaceted patient support and customized adverse effect mitigation plans informed by risk stratifying data may best address these common challenges.

Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.